Designing Stable Bacillus anthracis Antigens with a View to Recombinant Anthrax Vaccine Development.

ABSTRACT: Anthrax is a disease caused by Bacillus anthracis that affects mammals, including humans. Recombinant B. anthracis protective antigen (rPA) is the most common basis for modern anthrax vaccine candidates. However, this protein is characterised by low stability due to proteolysis and deamidation. Here, for the first time, two modification variants leading to full-size rPA stabilisation have been implemented simultaneously, through deamidation-prone asparagine residues substitution and by inactivation of proteolysis sites. Obtained modified rPA (rPA83m) has been demonstrated to be stable in various temperature conditions. Additionally, rPA1+2 containing PA domains I and II and rPA3+4 containing domains III and IV, including the same modifications, have been shown to be stable as

SUBMITTER: Ryabchevskaya EM 

PROVIDER: S-EPMC9025368 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature